CheckMate 274 — Adjuvant nivolumab versus placebo after radical surgery for high-risk muscle-invasive urothelial carcinoma

Phase 3 · Bladder Cancer, Urothelial Carcinoma

Population

High-risk muscle-invasive urothelial carcinoma of the bladder or upper urinary tract after radical surgery.

Primary Endpoint

Disease-free survival

Rationale

Many patients relapse after surgery for muscle-invasive urothelial cancer despite neoadjuvant chemotherapy, and no adjuvant therapy was established. CheckMate 274 tests whether adjuvant nivolumab lowers recurrence.

What It Could Change

Established adjuvant nivolumab as an option after surgery; ongoing follow-up defines the overall survival benefit.